Login / Signup

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.

Christopher Ernest Maitland GriffithsKim A PappMichael SongMegan MillerYin YouYaung-Kaung ShenChenglong HanAndrew Blauvelt
Published in: The Journal of dermatological treatment (2020)
High efficacy response rates were maintained through four years of continuous guselkumab treatment for psoriasis.
Keyphrases
  • early onset
  • combination therapy
  • high intensity
  • atopic dermatitis
  • smoking cessation